Bluejay Therapeutics
Brelovitug, a therapeutic for chronic hepatitis delta virus infection
- Sector
- Biotech
- Headquarters
- SAN MATEO, CA
- Founded
- 2019
- Latest Form D
- $182M, May 2024
- Total capital
- $222M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $222M
- 3 Form D · last May 2024
- 30 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 15 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$182M
- Private capital raisedForm D · SEC · 2nd filing$20.5M
- Private capital raisedForm D · SEC · 1st filing$19.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Alon LazarusDirectorNamed in SEC Form D filings
- Dajun YangDirectorNamed in SEC Form D filings
- Dan EstesDirectorNamed in SEC Form D filings
- Jianqing LiDirectorNamed in SEC Form D filings
- Keting ChuExecutive Officer, DirectorNamed in SEC Form D filings
- Nancy HongDirectorNamed in SEC Form D filings
Show all 10 people
- Pascal KroteeDirectorNamed in SEC Form D filings
- Ting J. JiaDirectorNamed in SEC Form D filings
- Wen ChenDirectorNamed in SEC Form D filings
- William J. RutterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 15- Pending17-BETA-HYDROXYSTEROID Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofUSPTOApplication 18747436
- PendingFusion Proteins Containing IL21 Muteins For Treating Cancer And Viral DiseasesUSPTOApplication 18762555
- PendingFatty Acid Synthase Inhibitors And Methods Of Use ThereofUSPTOApplication 63736470
Show all 15 patent records
- 17-BETA-HYDROXYSTEROID Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofJan 23, 2025 · Application 18747436Pending
- Fusion Proteins Containing IL21 Muteins For Treating Cancer And Viral DiseasesJan 9, 2025 · Application 18762555Pending
- Fatty Acid Synthase Inhibitors And Methods Of Use ThereofApplication 63736470Pending
- Fusion Proteins Containing IL21 Muteins For Treating Cancer And Viral DiseasesApplication PCTUS2024036618Pending
- 17-BETA-HYDROXYSTEROID Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofApplication PCTUS2024034555Pending
- Anti-hbsag Antibody For Treatment Of Chronic Hepatitis DApplication PCTUS2024031755Pending
- Fusion Proteins Containing IL21 Muteins For Treating Cancer And Viral DiseasesApplication 63572826Pending
- 17-BETA-HYDROXYSTEROID Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofApplication 63568312Pending
- Indazole Pyridone Compounds And Uses ThereofApplication PCTUS2023075889Pending
- Fusion Proteins Containing IL21 Muteins For Treating Cancer And Viral DiseasesApplication 63511810Pending
- 17-BETA-HYDROXYSTEROID Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofApplication 63509027Pending
- Anti-HBsAg antibody for treatment of chronic hepatitis DApplication 63505425Pending
- Fatty Acid Synthase Inhibitors And Methods Of Use ThereofApplication PCTUS2025060495Pending
- Indazole Pyridone Compounds And Uses ThereofApplication 63378354Pending
- Fatty Acid Synthase Inhibitors And Methods Of Use ThereofApplication 63929607Pending
Related companies, and why
- Corridor Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Processa Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- IRIDIA, INC.Similar federal contract value in Biotech · null in contracts
- STINGINN, LLCSimilar federal contract value in Biotech · null in contracts
- NOVICI BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- AERIE PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .